Pharvaris maps trial roadmap, cash runway into 2028

 

Pharvaris reports Q1 2026 results with non-GAAP EPS $-0.69 (+27% YoY) and revenue $0, beats estimates, ends quarter with €247M cash and runway into 2028

• Cash runway into 2028 follows $132 million equity raise completed before March 31.
• Company plans NDA filing for deucrictibant IR in 1H 2026, reaffirming prior regulatory timeline.
• Pivotal CHAPTER-3 data for deucrictibant IR expected in 3Q 2026, in line with previous guidance.

https://finviz.com/quote?t=PHVS&p=d